AFP and Cirrhosis: Similarly, gender, tumor size ≤5cm, without HBV/HCV infection, none of cirrhosis, low or middle level differentiation, positive MVI, and AFP<400 appeared to influence the advantages of neo-adjuvant therapy on PFS, but again without statistical significance.